You can’t say 2016 was a boring year. In addition to highlighting the best and worst for biopharma – the Cures legislation and accelerated regulatory paths, along with the disastrous Bial study and Alzheimer’s disappointments – the year heralded changes in the global political landscape that will begin playing out in 2017. Read More
DUBLIN – Chicago Cubs fans excepted, 2016 has been a bad year for many for a whole host of reasons. The travails of the Australian cell therapy developer Mesoblast Ltd. may not have registered broadly, but the firm has had a torrid year. Read More
HONG KONG – With an eye on an innovative biologic therapy that fulfills an unmet need in Asia, Shanghai-based biotech Imab purchased the exclusive Asian rights for a potential biologic drug for autoimmune diseases from Swiss company Ferring Pharmaceuticals SA. Read More
Intarcia Therapeutics Inc., of Boston, said it completed its second close of a series EE financing, raising an additional $206 million, and entered a relationship with the Bill & Melinda Gates Foundation to help prevent the spread of HIV in sub-Saharan Africa and other countries where the HIV epidemic is most severe. Read More
Tetralogic Pharmaceuticals Corp., of Paoli, Pa., and its wholly owned subsidiary said they completed the sale to Medivir AB, of Stockholm, of the SMAC mimetic program, including clinical-stage asset birinapant and topical HDAC inhibitor remetinostat. Read More
The U.S. Drug Enforcement Administration (DEA) issued a final rule updating its regulations for the import and export of tableting and encapsulating machines, controlled substances and listed chemicals. Read More
Biocardia Inc., of San Carlos, Calif., initiated a randomized, controlled pivotal trial of CardiAMP, its investigational autologous, minimally processed bone marrow cell therapy for heart failure. Read More
